Zuranolone is a new FDA approved medication for postpartum depression, a condition affecting 20% of postpartum women. In this episode, we'll cover the science behind the medication - the mechanism of how it works - the data and research that led to the approval, and four different aspects that require additional information and study to figure out who is going to be the ideal patient for this new and exciting treatment tool.
To learn more about me and my reproductive & integrative psychiatry clinic helping patients across California, please visit - AnnaGlezerMD.com
To sign up for the Fellowship in Reproductive & Integrative Psychiatry, please visit: PsychiatryFellowship.com
Links: AJP Zuranolone for PPD Article: https://pubmed.ncbi.nlm.nih.gov/37491938/